ASH 2024 | MRD monitoring for Ph+ ALL in the GIMEMA ALL2820 trial
Sabina Chiaretti
• 7 Dec 2024
Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, shares insights into the use of measurable residual disease (MRD) monitoring in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in the setting of the GIMEMA ALL2820 trial (NCT04722848). Dr Chiaretti notes that immunoglobulin T-cell receptor genes were monitored in 85% of patients, although there was no conclusive evidence that this approach was more effective in predicting relapse. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
